Claudia Ielo

Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?

Alessandra Tedeschi, Anna Maria Frustaci, Francesca Romana Mauro et al. · Blood Advances · 2021 · 30 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Francesca Romana Mauro, Diana Giannarelli, Andrea Visentin et al. · Cancers · 2021 · 26 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study

Idanna Innocenti, Gianluigi Reda, Andrea Visentin et al. · Haematologica · 2022 · 20 citations · Full text

Pharmacy, Hematology, Oncology +14

RR6 prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real-life cohort

Emilia Scalzulli, Claudia Ielo, Cristina Luise et al. · Blood Advances · 2022 · 16 citations · Full text

Medicine, Oncology, Pharmacology +10

Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia

Alessandro Nanni Costa, Elisabetta Abruzzese, Roberto Latagliata et al. · Journal of Clinical Medicine · 2024 · 10 citations · Full text

Medicine, Geriatric Medicine, Pharmacotherapy +13